FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine. Group of inventions involves the use of lisuride or terguride or their enantiomers, or their salts or hydrates for treating and preventing pulmonary arterial hypertension, endogenic or exogenic induced glomerular sclerosis, as well as secondary Reynaud's syndrome; the use of lisuride or terguride or their enantiomers, or their salts or hydrates for treating and preventing said diseases; a pharmaceutical composition for treating and preventing said diseases containing a compound specified in a group consisting of lisuride, terguride, their enantiomers, as well as their salts or hydrates, together with a pharmaceutically compatible carriers, excipients and/or solvents.
EFFECT: group of inventions provides higher therapeutic and preventive effectiveness.
6 cl, 10 ex, 3 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC COMPOSITIONS CONTAINING MACITENTAN | 2009 |
|
RU2519161C2 |
| DIARYLCARBAMIDE FOR TREATING PULMONARY HYPERTENSION | 2006 |
|
RU2431484C2 |
| HYPOTENSIVE COMBINATION OF VALSARTAN AND CALCIUM CANAL BLOCKERS | 1999 |
|
RU2450813C2 |
| HYPOTENSIVE COMBINATION OF VALSARTAN AND CALCIUM CHANNEL BLOCKING AGENT | 1999 |
|
RU2243768C2 |
| HUMAN ALDOSTERONE SYNTHASE (CYP11B2) INHIBITORS | 2023 |
|
RU2824362C1 |
| MEDICINAL AGENT FOR HYPERTENSION TREATMENT | 2000 |
|
RU2270679C2 |
| AGENT FOR TREATING PULMONARY HYPERTENSION | 2023 |
|
RU2813890C1 |
| PHARMACEUTICAL COMPOSITION INCLUDING RENIN INHIBITOR, CALCIUM CHANNEL BLOCKER AND DIURETIC | 2003 |
|
RU2316318C2 |
| HUMAN CYTOCHROME 11B2 INHIBITORS | 2022 |
|
RU2789610C1 |
| HUMAN CYTOCHROME 11B2 INHIBITORS | 2022 |
|
RU2800378C1 |
